Topical Immunomodulator Step Therapy Program

Size: px
Start display at page:

Download "Topical Immunomodulator Step Therapy Program"

Transcription

1 Topical Immunomodulator Step Therapy Program Policy Number: Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide coverage for topical immunomodulators when the following criteria are met. The topical immunomodulators affected are: Elidel (pimecrolimus cream) Protopic (tacrolimus ointment) Generic tacrolimus ointment When Policy Topic is covered This step therapy program has been developed to encourage the use of a topical corticosteroid (brand or generic) prior to pimecrolimus cream or tacrolimus ointment. If the step therapy rule is not met, coverage will be determined by prior authorization criteria. Automation: This program uses one topical steroid (brand or generic) in the previous 130 days as a surrogate marker. Step 1: topical corticosteroids (brand or generic) Step 2: tacrolimus ointment, Protopic, Elidel Criteria 1. If the patient has tried one prescription topical corticosteroid (brand or generic), then authorization for a Step 2 agent may be given. 2. Authorization for a Step 2 agent may be given if the patient has a dermatologic condition on or around the face, eyes/eyelids, axilla, or genitalia Topical corticosteroids may cause skin atrophy. The risk for this adverse event increases when these agents are used on thinner skin, in areas such as the face or skin folds. 5 Topical immunomodulators have not been found to cause skin atrophy. 1,5 The 2014 American Academy of Dermatology (AAD) Guidelines of Care for the Management of AD indicate that topical immunomodulators are effective for acute and chronic AD treatment, especially in patients with AD in sensitive areas (e.g., face, genitalia, skin folds), steroid-refractory AD, steroid-induced atrophy, or a history of long-term uninterrupted topical steroid use. 3. Authorization for a Step 2 agent may be given if the patient has steroid-induced rosacea. Preliminary reports indicate 7 to 10 days of therapy with topical tacrolimus (extemporaneously compounded) is effective for steroid-induced rosacea when combined with avoidance of all other topical therapy including topical corticosteroids In one small (n = 18), investigator-blind, split-face study, topical pimecrolimus (formulation not specified) was effective in treating steroid-induced rosacea. 12 In another small (n = 35), open-label study, topical pimecrolimus (formulation not specified) was effective

2 in treating steroid-induced rosacea. 13 The American Acne & Rosacea Society (AARS) consensus guidelines on the management of rosacea (2014) state that both tacrolimus ointment and Elidel cream have been used in the treatment of patients with steroid-induced rosacea. 14 When used in combination with steroid discontinuation, these agents have been observed to reduce erythema and other rosacea symptoms. 4. No other exceptions are recommended. When Policy Topic is not covered The use of topical immunomodulators is considered investigational for all other indications. Considerations Topical immunomodulators require prior authorization through the Clinical Pharmacy Department. This Blue Cross and Blue Shield of Kansas City policy Statement was developed using available resources such as, but not limited to: Food and Drug Administration (FDA) approvals, Facts and Comparisons, National specialty guidelines, Local medical policies of other health plans, Medicare (CMS), Local providers Description of Procedure or Service Atopic Dermatitis (AD) AD is a genetically transmitted, chronic inflammatory skin disease that affects 10% to 20% of children and 1% to 3% of adults. 1 Pruritis, scratching, and chronic and/or relapsing eczematous lesions are major hallmarks of the disease. In infants and young children, there is a characteristic pattern of involvement of the face, neck, and extensor skin surfaces. In older children and adults, the skin lesions often involve lichenification and are usually localized to the flexural folds of the extremities. The diagnosis of AD is based on clinical presentation rather than results of diagnostic testing. The effective management of AD involves a combination of trigger avoidance, measures to restore skin barrier function (e.g., emollients), and anti-inflammatory medications (e.g., topical corticosteroids, Protopic, and Elidel). Protopic and Elidel are topical calcineurin inhibitors (immunomodulators) indicated as second-line therapy for the short-term and non-continuous chronic treatment of AD in non-immunocompromised patients who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. 2-3 Protopic is indicated for moderate to severe AD while Elidel is indicated for mild to moderate AD. Protopic 0.03% ointment and Elidel are indicated in adults and children aged 2 years. Although there are data documenting the Protopic 0.1% strength s safety and efficacy in children, this product is not approved for use in pediatric patients. Neither Protopic nor Elidel are indicated for use in children < 2 years of age; however, both agents have been studied in this patient population. 1 Based on concerns of the potential carcinogenicity (skin cancer and lymphomas) that may be associated with using a topical immunomodulator continuously over a prolonged period of time, a Black Box Warning was added to Elidel and Protopic product labeling. 2-3 There have been no empirical data to date definitively linking Elidel and Protopic to an increased cancer risk in humans and a causal relationship has not been established. 2-5 A case-control study of nearly 300,000 patients with AD did not demonstrate an increased risk of lymphoma in patients who received therapy with a topical calcineurin inhibitor. 1 There are data in three different animal species which demonstrated that the risk of cancer increased as the amount of drug given increased and that immunosuppressant use in transplant patients has led to an increase in cancer incidence. 2-3 Data reviewed also included a small number of reports of cancers in children and adults. The Food and Drug Administration (FDA) Pediatric Advisory Committee expressed concern over the widespread off-label use of these agents as first-line treatment and in children 2 years of age. 6 The FDA emphasized that these agents should be used only as directed and as indicated and only after other eczema treatments have failed to work. The

3 prescribing information for both products was updated to clarify that these drugs are recommended for use as second-line therapy for the short-term and non-continuous treatment in nonimmunocompromised patients. Elidel and Protopic should be used for short periods of time and patients should use only the minimum amount necessary to control symptoms. Rationale According to the 2012 Joint Task Force (American Academy of Allergy, Asthma, and Immunology [AAAAI], the American College of Allergy, Asthma, and Immunology [ACAAI], and the Joint Council of Allergy, Asthma, and Immunology [JCAAI]) AD practice parameter, topical corticosteroids are appropriate for the vast majority of patients. 1 The 2014 American Academy of Dermatology (AAD) Guidelines of Care for the Management of AD also indicate that topical steroids are the mainstay of therapy for AD in both adults and children. 5 The intensity of management and treatment of AD is dictated by the severity of illness. 1 Clinicians should use a multifaceted approach that includes skin hydration, topical anti-inflammatory medications, antipruritic therapy, antibacterial measures, and elimination of exacerbating factors. Moisturizers should be recommended as first-line therapy. If AD is not controlled by moisturizers alone, a topical corticosteroid should be used. 1,5 Low-potency corticosteroids are recommended for maintenance therapy, while intermediate- and high-potency corticosteroids should be used for the treatment of exacerbation over short periods of time. 1 Potent fluorinated corticosteroids should not be used on the face, eyelids, genitalia, and intertriginous areas or in young infants; a low-potency corticosteroid preparation is generally recommended for these areas. Ultrahigh-potency corticosteroids should only be used for very short periods (1 to 2 weeks) and in nonfacial, non-skinfold areas. The Joint Task Force guidelines note that Protopic should be considered for AD that is unresponsive to low-potency topical steroids. 1 Protopic, unlike topical glucocorticoids, is not atrophogenic and has a greater therapeutic margin of safety than medium-strength corticosteroids for facial and eyelid eczema. Studies have demonstrated that Protopic 0.1% ointment has the strength of a mid-potency topical corticosteroid and should be considered first-line therapy for facial eczema where treatment with corticosteroids is limited to low-potency corticosteroids due to safety concerns. According to guidelines, Elidel decreases the number of AD flares, reduces the need for corticosteroids, does not cause skin atrophy, and controls pruritus. The AAD guidelines also confirm that the topical immunomodulators are effective for acute and chronic AD treatment, especially in patients with steroidrefractory AD, AD in sensitive areas (e.g., face, genitalia, skin folds), steroid-induced atrophy, and longterm uninterrupted topical steroid use. 5 Furthermore, the AAD guidelines recommend intermittent use of a topical immunomodulator as maintenance therapy (two to three times per week) to help prevent relapses in areas that commonly flare. In this setting, the topical immunomodulators are more effective treatment than emollients alone and also reduce the need for topical corticosteroids. Off-Label Use There is widespread off-label use of the topical immunomodulators in several dermatologic conditions. In these conditions, topical immunomodulators are used when patients have failed standard therapy or in patients with contraindications to standard therapy agents. Data on the use of the topical immunomodulators are available in patients with lichen planus, cutaneous lupus erythematosus (CLE), psoriasis, and vitiligo, as well as numerous other rare dermatologic conditions. 4,7-9 In these conditions, topical corticosteroids remain first line-therapy, with tacrolimus and Elidel utilized as second-line therapy when patients have failed primary treatment. References 1. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update J Allergy Clin Immunol. 2013;131: Elidel cream [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North American LLC; March Protopic ointment [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; May Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;60:

4 5. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Section 2: management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1): FDA Talk Paper. FDA issues public health advisory informing health care providers of safety concerns associated with theuse of two eczema drugs, Elidel and Protopic. March 10, Davari P, Hsiao HH, Fazel N. Mucosal lichen planus: an evidence-based treatment update. Am J Clin Dermatol 2014;15(3): Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of cutaneous lupus erythematosus: review and assessment of treatment benefits based on Oxford Centre for Evidence-Based Medicine criteria. J Clin Aesthet Dermatol. 2013;6(1): Taieb A, Alomar A, Bohm M, et al. Guidelines for the management of vitiligo. The European Dermatology Forum consensus. Brit J Dermatol. 2013;168(1): Ruzicka T, Assmann T, Lebwohl M. Potential future dermatological indications for tacrolimus ointment. Eur J Dermatol. 2003;13: Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44: Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. Br J Dermatol. 2008;158(5): Chu CY. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. J Eur Acad Dermatol Venereol. 2007;21: Del Rosso JQ, Thiboutot D, Gallo R. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93(3): Other References Utilized Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14: Billing Coding/Physician Documentation Information Topical immunomodulators are considered a pharmacy benefit Additional Policy Key Words Policy Number: Policy Implementation/Update Information 08/2013 New Policy titled Topical Immunomodulator Step Therapy Program 08/2015 Annual Review- updated References; no changes in policy statement 12/2015 Added generic tacrolimus ointment 08/2016 Annual Review- updated References; no changes in policy statement 08/2017 Annual review- no changes to policy statement State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The

5 medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Topical Doxepin Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Topical Doxepin Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Topical Doxepin Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Topical Doxepin (For Individuals Who Purchased BlueCare/KS Solutions/EPO Products) Prime

More information

Takhzyro (lanadelumab-flyo)

Takhzyro (lanadelumab-flyo) Takhzyro (lanadelumab-flyo) Policy Number: 5.01.675 Last Review: 1/2019 Origination: 1/2019 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Takhzyro

More information

Influenza Therapies. Considerations Prescription influenza therapies require prior authorization through pharmacy services.

Influenza Therapies. Considerations Prescription influenza therapies require prior authorization through pharmacy services. Influenza Therapies Policy Number: 5.01.515 Last Review: 10/2017 Origination: 10/2002 Next Review: 10/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for influenza

More information

Atopic Eczema with detail on how to apply wet wraps

Atopic Eczema with detail on how to apply wet wraps Atopic Eczema with detail on how to apply wet wraps Dr Carol Hlela Consultant Dermatologist Head of Unit, Department of Dermatology, Paediatrics Red Cross Children s Hospital, UCT Red Cross War Memorial

More information

Vosevi (sofosbuvir/velpatasvir/voxilaprevir)

Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide

More information

Ingrezza (valbenazine)

Ingrezza (valbenazine) Ingrezza (valbenazine) Policy Number: 5.01.635 Last Review: 7/2018 Origination: 07/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Ingrezza

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ultraviolet Light Therapy in the Home Setting(UVB) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ultraviolet_light_therapy_in_the_home 3/1996 11/2017 11/2018

More information

Topical Doxepin Prior Authorization with Quantity Limit Program Summary

Topical Doxepin Prior Authorization with Quantity Limit Program Summary Topical Doxepin Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-3 Agent(s) Indication(s) Dosage & Administration Doxepin 5% cream Prudoxin (doxepin) cream 5% KS_PS_Topical_Doxepin_PAQL_ProgSum_AR1018

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Policy: Atopic Dermatitis and Topical Antipsoriatics Reference Number: TCHP.PHAR.18004 Effective Date: 01.01.18 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Technology Appraisals and Guidance Information Services Static List Review (SLR) Title and TA publication number of static topic: Final decision: TA82;

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Antigen Leukocyte Antibody Test

Antigen Leukocyte Antibody Test Antigen Leukocyte Antibody Test Policy Number: 2.01.93 Last Review: 4/2014 Origination: 4/2014 Next Review: 4/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for

More information

Assessing the Current Treatment of Atopic Dermatitis: Unmet Needs

Assessing the Current Treatment of Atopic Dermatitis: Unmet Needs Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Managing and Minimizing Flare-ups in Atopic Dermatitis

Managing and Minimizing Flare-ups in Atopic Dermatitis Managing and Minimizing Flare-ups in Atopic Dermatitis Importance of the skin barrier & how commonly used drugs are impacting it Dr. Benjamin Barankin, MD FRCPC Medical Director & Founder of Toronto Dermatology

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Cosentyx, Cosentyx Sensoready) Reference Number: HIM.PA.SP29 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See

More information

Poteligeo (mogamulizmuab-kpkc)

Poteligeo (mogamulizmuab-kpkc) Poteligeo (mogamulizmuab-kpkc) Policy Number: 5.02.556 Last Review: 1/2019 Origination: 1/2019 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Poteligeo

More information

Clinical Policy: Brodalumab (Siliq) Reference Number: CP.PHAR.375 Effective Date: Last Review Date: 05.18

Clinical Policy: Brodalumab (Siliq) Reference Number: CP.PHAR.375 Effective Date: Last Review Date: 05.18 Clinical Policy: (Siliq) Reference Number: CP.PHAR.375 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review

More information

Addyi (flibanserin) When Policy Topic is covered Coverage of Addyi is recommended in those who meet the following criteria:

Addyi (flibanserin) When Policy Topic is covered Coverage of Addyi is recommended in those who meet the following criteria: Addyi (flibanserin) Policy Number: 5.01.605 Last Review: 10/2018 Origination: 10/2015 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Addyi when

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Antigen Leukocyte Antibody Test

Antigen Leukocyte Antibody Test Antigen Leukocyte Antibody Test Policy Number: 2.01.93 Last Review: 4/2018 Origination: 4/2014 Next Review: 4/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for

More information

The Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah

The Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah The Itch That Rashes Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah 1 Conflict of Interest No conflict of interest Will discuss off label use of medications 2 3 Most likely diagnosis?

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)

More information

Hetlioz (tasimelteon)

Hetlioz (tasimelteon) Hetlioz (tasimelteon) Policy Number: 5.01.687 Last Review: 01/2019 Origination: 01/2019 Next Review: 01/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Hetlioz

More information

UPDATES IN ATOPIC DERMATITIS

UPDATES IN ATOPIC DERMATITIS UPDATES IN ATOPIC DERMATITIS Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute, Scottsdale, AZ LEARNING OBJECTIVES Discuss epidemiology, risk factors, and causes of

More information

What s Topical About Topicals?

What s Topical About Topicals? What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids

More information

Phototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])

Phototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV]) Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when

More information

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the

More information

Facet Arthroplasty. Policy Number: Last Review: 9/2018 Origination: 9/2009 Next Review: 3/2019

Facet Arthroplasty. Policy Number: Last Review: 9/2018 Origination: 9/2009 Next Review: 3/2019 Facet Arthroplasty Policy Number: 7.01.120 Last Review: 9/2018 Origination: 9/2009 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for total facet

More information

New Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003

New Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003 New Medicine Report Document Status Pimecrolimus Reviewed by Suffolk D&T RED- Hospital only Date of Last Revision 6 th March 2003 Approved Name Pimecrolimus Trade Name Elidel Manufacturer Novartis Legal

More information

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Atopic Dermatitis and Topical Antipsoriatics

Atopic Dermatitis and Topical Antipsoriatics Atopic Dermatitis and Topical Antipsoriatics Goal(s): Restrict dermatological drugs only for funded OHP diagnoses. Moderate/severe psoriasis and moderate/severe atopic dermatitis treatments are funded

More information

Clinical Policy: Acitretin (Soriatane) Reference Number: CP.PMN.40. Line of Business: Medicaid

Clinical Policy: Acitretin (Soriatane) Reference Number: CP.PMN.40. Line of Business: Medicaid Clinical Policy: (Soriatane) Reference Number: CP.PMN.40 Effective Date: 08/10 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

What is atopic dermatitis?

What is atopic dermatitis? What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Prime Therapeutics will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6514ks-ingr.pdf

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017

More information

Intracellular Micronutrient Analysis

Intracellular Micronutrient Analysis Intracellular Micronutrient Analysis Policy Number: 2.04.73 Last Review: 1/2019 Origination: 1/2013 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage

More information

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

The safety and effectiveness of Dupixent in pediatric patients have not been established (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior

More information

PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: , VERSION 12.0

PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: , VERSION 12.0 PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: 23.11.2016, VERSION 12.0 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Eczema mainly affects children

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Rayos) Reference Number: CP.CPA.273 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264

Clinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264 Clinical Policy: (Stelara) Reference Number: CP.PHAR.264 Effective Date: 08/16 Last Review Date: 05/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date: Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Original Policy Date

Original Policy Date MP 2.01.07 Psoralens with Ultraviolet A (PUVA) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed by consensus/12:2013 Return to Medical Policy

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization

More information

PNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab

PNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Light Therapy for Dermatologic Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: light_therapy_for_dermatologic_conditions 5/2012 11/2017 11/2018

More information

Clinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:

Clinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date: Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Avastin (bevacizumab)

Avastin (bevacizumab) Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests

More information

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18 Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 11.18

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 11.18 Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Transtympanic Micropressure Applications as a Treatment of Meniere s Disease

Transtympanic Micropressure Applications as a Treatment of Meniere s Disease Transtympanic Micropressure Applications as a Treatment of Meniere s Disease Policy Number: 1.01.23 Last Review: 8/2014 Origination: 2/2006 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests

More information

Prescribing Information

Prescribing Information Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division

More information

Surgical Treatment of Bilateral Gynecomastia

Surgical Treatment of Bilateral Gynecomastia Surgical Treatment of Bilateral Gynecomastia Policy Number: 7.01.13 Last Review: 4/2018 Origination: 4/2006 Next Review: 4/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

Promacta (eltrombopag)

Promacta (eltrombopag) Promacta (eltrombopag) Policy Number: 5.01.542 Last Review: 5/2018 Origination: 6/2013 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Promacta

More information

Literature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy

Literature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

PNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab

PNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

use of Calcineurin University of Ottawa Canada The 7 th International Congress on Autoimmunity. Ljubljana- Slovenia. May 5-9, 2010

use of Calcineurin University of Ottawa Canada The 7 th International Congress on Autoimmunity. Ljubljana- Slovenia. May 5-9, 2010 Safety Issues with the use of Calcineurin Inhibitors Tarek Salem MD Tarek Salem, MD University of Ottawa Canada The 7 th International Congress on Autoimmunity. Ljubljana- Slovenia. May 5-9, 2010 Disclaimer

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17

Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Policy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.

Policy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043. Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate

More information

Nonpharmacologic Treatment of Rosacea Corporate Medical Policy

Nonpharmacologic Treatment of Rosacea Corporate Medical Policy Nonpharmacologic Treatment of Rosacea Corporate Medical Policy File Name: Nonpharmacologic Treatment of Rosacea. File Code: UM.SURG.11 Last Review: 01/2019 Next Review: 01/2020 Effective Date: 04/01/2019

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

* Autoantibody positive (i.e. antinuclear antibody or ANA titre 1:80 or anti-double stranded (ds) DNA antibody 30 IU/mL)

* Autoantibody positive (i.e. antinuclear antibody or ANA titre 1:80 or anti-double stranded (ds) DNA antibody 30 IU/mL) Benlysta (belimumab) Policy Number: 5.02.509 Last Review: 05/2018 Origination: 06/2011 Next Review: 05/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Benlysta

More information

Peripheral Subcutaneous Field Stimulation

Peripheral Subcutaneous Field Stimulation Peripheral Subcutaneous Field Stimulation Policy Number: 7.01.139 Last Review: 9/2014 Origination: 7/2013 Next Review: 1/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide

More information

Dynamic Spinal Visualization and Vertebral Motion Analysis

Dynamic Spinal Visualization and Vertebral Motion Analysis Dynamic Spinal Visualization and Vertebral Motion Analysis Policy Number: 6.01.46 Last Review: 2/2019 Origination: 2/2006 Next Review: 2/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)

More information

Update on emollients

Update on emollients Update on emollients Amal Mhanna, MD Pediatric Dermatologist Clemenceau Medical Center Disclosure: I was a member of an advisory board y for J&J and received honoraria. Emollients and moisturizers are

More information

REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS US DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS US DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS Executive Summary Sales for Atopic Dermatitis 2012 in US The US Atopic dermatitis market was worth approximately $1.35 billion

More information

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Effective Date: November 2008 Last Review Date: January 2017 See Important Reminder at the

More information

Vertebral Axial Decompression

Vertebral Axial Decompression Vertebral Axial Decompression Policy Number: 8.03.09 Last Review: 11/2017 Origination: 11/2005 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage

More information

Uloric Step Therapy Program

Uloric Step Therapy Program Uloric Step Therapy Program Policy Number: 5.01.584 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for brand

More information

DUPIXENT (dupilumab) subcutaneous injection

DUPIXENT (dupilumab) subcutaneous injection DUPIXENT (dupilumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

TCIs are only available on prescription and are usually started by a dermatology specialist.

TCIs are only available on prescription and are usually started by a dermatology specialist. (TCIs) What are topical calcineurin inhibitors? Topical calcineurin inhibitors are treatments that alter the immune system and have been developed for controlling eczema. There are two types available:

More information

Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis

Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis Original Article Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis Md Alauddin Khan *, Lubna Khondker **, Dilshad

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

New and emerging trends in the treatment of atopic dermatitis

New and emerging trends in the treatment of atopic dermatitis REVIEW New and emerging trends in the treatment of atopic dermatitis Christina M Gelbard 1 Adelaide A Hebert 1,2 1 Departments of Dermatology; 2 Pediatrics, University of Texas-Houston, Houston, TX, USA

More information

Bioimpedance Devices for Detection and Management of Lymphedema

Bioimpedance Devices for Detection and Management of Lymphedema Bioimpedance Devices for Detection and Management of Lymphedema Policy Number: 2.01.82 Last Review: 5/2017 Origination: 1/2011 Next Review: 5/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPMN.167

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPMN.167 Clinical Policy: (Stelara) Reference Number: ERX.SPMN.167 Effective Date: 10/16 Last Review Date: 12/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

1 Introduction. Lee T. Zane 1 Matilda H. Hughes

1 Introduction. Lee T. Zane 1 Matilda H. Hughes Am J Clin Dermatol (2016) 17:519 526 DOI 10.1007/s40257-016-0204-6 ORIGINAL RESEARCH ARTICLE Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2104-4 Program Prior Authorization/Medical Necessity Medication Taltz (ixekizumab) P&T Approval Date 8/2016, 5/2017, 2/2018 Effective

More information

Teledermatology Paediatric eczema. Dr Carolyn Charman Consultant Dermatologist Royal Devon and Exeter Hospital

Teledermatology Paediatric eczema. Dr Carolyn Charman Consultant Dermatologist Royal Devon and Exeter Hospital Teledermatology Paediatric eczema Dr Carolyn Charman Consultant Dermatologist Royal Devon and Exeter Hospital NHS e-referral teledermatology Rapid access to diagnosis / management advice from local integrated

More information

Ocaliva (obeticholic acid tablets)

Ocaliva (obeticholic acid tablets) Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

Prescribing Information. Taro-Clobetasol. Taro-Clobetasol

Prescribing Information. Taro-Clobetasol. Taro-Clobetasol Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate PACKAGE LEAFLET: INFORMATION FOR THE USER Flutarzole 0,05% w/w cream, Fluticasone propionate 1. IDENTIFICATION OF THE MEDICINAL PRODUCT 1.1. Trade name Flutarzole 1.2. Composition Active substance: Fluticasone

More information

(minutes for web publishing)

(minutes for web publishing) Dermatology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 20 October 2017 (minutes for web publishing) Dermatology Subcommittee minutes are published in accordance

More information

Nutrient/Nutritional Panel Testing

Nutrient/Nutritional Panel Testing Nutrient/Nutritional Panel Testing Policy Number: 2.04.136 Last Review: 10/2017 Origination: 10/2015 Next Review: 10/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage

More information

Chenodal (chenodiol)

Chenodal (chenodiol) Chenodal (chenodiol) Policy Number: 5.01.549 Last Review: 04/2018 Origination: 06/2013 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Chenodal

More information